REG-Arix Bioscience PLC Arix Bioscience plc Announces Changes to Board of Directors

Arix BioscienceAnnouncement

10/08/2022 07:15

============

   Arix Bioscience PLC (ARIX)
   Arix Bioscience plc Announces Changes to Board of Directors

   10-Aug-2022 / 07:01 GMT/BST
   Dissemination of a Regulatory Announcement, transmitted by EQS Group.
   The issuer is solely responsible for the content of this announcement.

   ══════════════════════════════════════════════════════════════════════════

    

                                        

                                        

          Arix Bioscience plc Announces Changes to Board of Directors

                                        

    Dr Debra Barker appointed as Senior Independent Director, replacing Sir
                                Michael Bunbury

    Dr Benny Soffer and Andrew Smith appointed as Independent Non-Executive
                                   Directors

                                        

   LONDON, 10  August 2022:  Arix Bioscience  plc (“Arix”  or the  “Company”)
   (LSE: ARIX), is pleased to announce  the appointments of Dr Debra  Barker,
   Dr Benny  Soffer, and  Andrew  Smith as  Senior Independent  Director  and
   Non-Executive Directors respectively  with immediate effect.  In light  of
   these appointments  which bring  the  Board into  compliance with  the  UK
   Corporate Governance Code, Sir Michael Bunbury is resigning from the Board
   with immediate effect. Debra Barker will Chair the Company’s  Remuneration
   Committee and Andrew Smith will Chair the Company’s Audit Committee.

    

   Debra Barker is a seasoned international life sciences executive with more
   than 25 years’ senior  and board experience from  start-up biotech to  big
   pharma companies,  having  held  a  number  of  senior  drug  development,
   strategic and operational roles in Novartis, Roche, SmithKline Beecham and
   Knoll. Debra is currently Non-Executive Director of three publicly  listed
   biotechnology companies: Destiny Pharma plc, BergenBio in Norway and  most
   recently, CureVac AG  in Germany.  Debra has a  Diploma in  Pharmaceutical
   Medicine and  received a  MSc in  Immunology from  the King's  College  in
   London and a Medical Degree from the Queens’ College, Cambridge, UK.

   Benny Soffer, MD is Co-Founder and Chief Investment Officer of  Consonance
   Capital  Management,   a  healthcare-focused   public  equity   investment
   management firm. He previously completed a residency in internal  medicine
   at Yale and  served in  a variety of  managerial roles  at Yale-New  Haven
   Hospital.  Dr  Soffer is  a Clinical  Assistant Professor  of Medicine  at
   Weill Cornell Medicine, receiving his MD  at Emory University and his  MBA
   at Yale University.

   Andrew Smith  is an  internationally experienced  chief financial  officer
   with strong financial and operational experience in US, Swiss and UK-based
   biotech and pharmaceutical companies. Andrew is currently Chief  Financial
   Officer  of   Santhera   Pharmaceuticals,   the   Swiss-based   speciality
   pharmaceutical  company,  having  previously  held  a  number  of   senior
   operational  and   financial   roles  in   companies   including   Allecra
   Therapeutics, Sucampo Pharmaceuticals Inc., and Retroscreen Virology  (Now
   HVIVO Ltd).  He is  a  Fellow of  the  Chartered Institute  of  Management
   Accountants and  a  Chartered  Global Management  Accountant.  He  studied
   business and accounting  at Liverpool  John Moores  University and  Durham
   University Business School.

    

   Peregrine Moncreiffe,  Chairman  of  the  Board of  Arix,  said:  “We  are
   delighted to welcome Debra, Benny and Andrew to the Board. Their range  of
   skills and experience serve to further reinforce and focus our  investment
   strategy, particularly following the creation of the Public  Opportunities
   Portfolio earlier this year, and we look forward to benefitting from their
   international industry, financial and operational expertise. I would  also
   like to thank Sir Michael Bunbury  for the stewardship he has provided  as
   Senior Independent Director over the last nine months and his  significant
   contribution to improving corporate governance at Arix.”

    

                                      ENDS 

    

   Enquiries

   For more information on Arix, please contact:

    

   Arix Bioscience plc

   +44 (0)20 7290 1050

   ir 1 @arixbioscience.com

    

   Powerscourt Group

   Sarah MacLeod, Ibrahim Khalil, Nick Johnson

   +44 (0)20 7250 1446

    2 arix@powerscourt-group.com

    

   About Arix Bioscience plc

   Arix Bioscience  plc  is  a  global venture  capital  company  focused  on
   investing in  breakthrough  biotechnology  companies  around  cutting-edge
   advances in life sciences.

    

   We collaborate  with exceptional  entrepreneurs and  provide the  capital,
   expertise, and  global  networks  to  help  accelerate  their  ideas  into
   important new treatments for patients. As a listed company, we are able to
   bring this exciting  growth phase of  our industry to  a broader range  of
   investors.  3 www.arixbioscience.com

    

    

    

    

    

   ══════════════════════════════════════════════════════════════════════════

   ISIN:           GB00BD045071
   Category Code:  BOA
   TIDM:           ARIX
   LEI Code:       213800OVT3AHQCXNIX43
   OAM Categories: 3.1. Additional regulated information required to be
                   disclosed under the laws of a Member State
   Sequence No.:   180279
   EQS News ID:    1416829


    
   End of Announcement EQS News Service

   ══════════════════════════════════════════════════════════════════════════

    4 fncls.ssp?fn=show_t_gif&application_id=1416829&application_name=news&site_id=reuters9

References

   Visible links
   1. mailto:charlotte@arixbioscience.com
   2. mailto:arix@powerscourt-group.com
   3. https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1416829&site_id=reuters9&application_name=news


============